ASLAN Pharmaceuticals Pte. Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ASLAN Pharmaceuticals Pte. Ltd. - overview
Established
2010
Location
Singapore, -, Singapore
Primary Industry
Pharmaceuticals
About
Founded in 2010, chaired by Carl Firth as CEO, and based in Singapore, ASLAN Pharmaceuticals Pte. Ltd is a clinical-stage immunology-focused biopharmaceutical company developing treatments and therapies focused on atopic dermatitis, and other immunology indications and autoimmune diseases. The company operates across Taiwan, China, and Australia. The company trades on NASDAQ under the ticker symbol ASLN.
ASLAN Pharmaceutical’s portfolio is led by ASLAN004, a monoclonal antibody targeting IL-13Ra1, a treatment for atopic dermatitis and asthma. ASLAN004 is in Phase 1 of the clinical trials. Additionally, the company’s pipeline includes ASLAN003, an oral inhibitor of DHODH in the development of autoimmune diseases such as Dengue and Zika viruses. The company is currently assessing the potential of ASLAN003 as a treatment for Covid-19.
As of 2021, the company has an AhR antagonist, a druggable transcription factor that acts as a master regulator of the immune system, in the discovery stage for oncology. The company plans to begin the Phase 2b study of ASLAN004 in the second half of 2021 and to roll out its cancer drug in China, the US, and Europe in the future.
Current Investors
Daiwa Corporate Investment, Top Taiwan Venture Capital, Milestone Capital
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.aslanpharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
ASLAN Pharmaceuticals Pte. Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | ASLAN Pharmaceuticals Pte. Ltd. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.